- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
MBI’s CT agent shows promise
A liver-specific CT contrast agent under development at Molecular Biosystems (MBI) was featured at the biannual Contrast Media Research Conference, held Sept. 13 through 17 in Woodstock, VT. Animal studies have shown that the agent, MB-840, could help
A liver-specific CT contrast agent under development at Molecular Biosystems (MBI) was featured at the biannual Contrast Media Research Conference, held Sept. 13 through 17 in Woodstock, VT. Animal studies have shown that the agent, MB-840, could help clinicians identify and monitor primary and metastatic liver tumors as small as 1 to 2 mm, whereas water-soluble CT contrast agents can detect tumors no smaller than 20 mm. MB-840 could also help physicians find diseases of the hepatobiliary system, MBI said. The San Diego, CA, company expects to begin clinical trials for the agent next year, according to Dr. Howard Dittrich, executive vice president. MBI also developed Optison, an ultrasound contrast agent cleared by the FDA in 1997 (SCAN 1/14/98).
Emerging Perspectives on PSMA PET Radiotracers: An Interview with Kenneth J. Pienta, MD
April 24th 2024In a recent interview, Kenneth J. Pienta, M.D., discussed the impact of piflufolastat F18, current directions in research with other PSMA-targeted radiotracers and future possibilities for the role of PSMA PET in the imaging paradigm for prostate cancer.
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.
